These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 37108130)

  • 1. Immunogenicity and Safety of Adjuvanted Recombinant Zoster Vaccine in Rheumatoid Arthritis Patients on Anti-Cellular Biologic Agents or JAK Inhibitors: A Prospective Observational Study.
    Venerito V; Stefanizzi P; Cantarini L; Lavista M; Galeone MG; Di Lorenzo A; Iannone F; Tafuri S; Lopalco G
    Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and influence on disease activity of recombinant zoster vaccine in patients with rheumatoid arthritis treated with DMARDs.
    Kojima S; Iwamoto T; Kobayashi Y; Kato M; Takizawa F; Ida T; Suzuki J; Toda Y; Miyachi K; Iwata A; Furuta S; Ikeda K; Nakajima H
    RMD Open; 2024 Feb; 10(1):. PubMed ID: 38388170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serologic immunogenicity and safety of herpes zoster subunit vaccine in patients with rheumatoid arthritis receiving Janus kinase inhibitors.
    Källmark H; Bergström T; Nagel J; Gullstrand B; Einarsson JT; Bengtsson AA; Kapetanovic MC
    Rheumatology (Oxford); 2024 Jul; 63(7):2024-2033. PubMed ID: 37851412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, and Humoral and Cell-mediated Immune Responses to Herpes Zoster Vaccine in Patients with Rheumatoid Arthritis.
    Koh JH; Lee J; Kim SH; Kwok SK; Ju JH; Park SH
    J Rheumatol; 2018 Apr; 45(4):465-469. PubMed ID: 29419465
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prior herpes zoster occurrence and high-dose corticosteroids increase herpes zoster risk in rheumatoid arthritis patients receiving janus kinase inhibitors in a retrospective and observational study.
    Chen PK; Chang SH; Chen YM; Chen HH; Huang PH; Huang CC; Yeo KJ; Lan JL; Chen DY
    Clin Rheumatol; 2024 Aug; 43(8):2503-2511. PubMed ID: 38954278
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs.
    Opdam MAA; Broeder ND; van den Bemt BJF; Mulder K; van de Wiel KM; van Ballegooijen H; van Crevel R; den Broeder AA
    Clin Rheumatol; 2024 Jun; 43(6):2133-2138. PubMed ID: 38703283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world comparative effectiveness of bDMARDs and JAK inhibitors in elderly patients with rheumatoid arthritis.
    Temmoku J; Migita K; Yoshida S; Matsumoto H; Fujita Y; Matsuoka N; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Watanabe H; Miyata M
    Medicine (Baltimore); 2022 Oct; 101(42):e31161. PubMed ID: 36281115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety profile of recombinant adjuvanted anti-herpes zoster vaccine (RZV) in high-risk groups: Data from active surveillance program. Puglia (Italy), 2021-23.
    Stefanizzi P; Moscara L; Palmieri C; Martinelli A; Di Lorenzo A; Venerito V; Germinario CA; Tafuri S
    Vaccine; 2024 Apr; 42(12):2966-2974. PubMed ID: 38582693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Safety and Immunogenicity of Live Zoster Vaccination in Patients With Rheumatoid Arthritis Before Starting Tofacitinib: A Randomized Phase II Trial.
    Winthrop KL; Wouters AG; Choy EH; Soma K; Hodge JA; Nduaka CI; Biswas P; Needle E; Passador S; Mojcik CF; Rigby WF
    Arthritis Rheumatol; 2017 Oct; 69(10):1969-1977. PubMed ID: 28845577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
    Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
    J Virol; 2021 May; 95(12):. PubMed ID: 33762414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunogenicity and the safety of the adjuvanted glycoprotein E (gE)-based recombinant vaccine against herpes zoster (RZV) in cancer patients during immunotherapy.
    Lasagna A; Mele D; Bergami F; Alaimo D; Dauccia C; Alessio N; Comolli G; Pasi F; Muzzi A; Novelli V; Baldanti F; Pedrazzoli P; Cassaniti I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2288282. PubMed ID: 38037900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy with JAK inhibitors or bDMARDs and the risk of cardiovascular events in the Dutch rheumatoid arthritis population.
    Popa CD; Opdam MAA; den Broeder N; van Ballegooijen H; Mulder K; van de Wiel KM; van Herwaarden N; Wientjes MHM; den Broeder AA
    Rheumatology (Oxford); 2024 Aug; 63(8):2142-2146. PubMed ID: 37796830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug retention of secondary biologics or JAK inhibitors after tocilizumab or abatacept failure as first biologics in patients with rheumatoid arthritis -the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Takeuchi T; Nagai K; Son Y; Amuro H; Onishi A; Jinno S; Hara R; Katayama M; Yamamoto K; Kumanogoh A; Hirao M
    Clin Rheumatol; 2020 Sep; 39(9):2563-2572. PubMed ID: 32162152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of the Adjuvanted Recombinant Zoster Vaccine: Persistence and Anamnestic Response to Additional Doses Administered 10 Years After Primary Vaccination.
    Hastie A; Catteau G; Enemuo A; Mrkvan T; Salaun B; Volpe S; Smetana J; Rombo L; Schwarz T; Pauksens K; Hervé C; Bastidas A; Schuind A
    J Infect Dis; 2021 Dec; 224(12):2025-2034. PubMed ID: 32502272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of Recombinant Zoster Vaccine in Patients with Inflammatory Bowel Disease.
    Satyam VR; Li PH; Reich J; Qazi T; Noronha A; Wasan SK; Farraye FA
    Dig Dis Sci; 2020 Oct; 65(10):2986-2991. PubMed ID: 31897892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of drug retention of TNF inhibitors, other biologics and JAK inhibitors in RA patients who discontinued JAK inhibitor therapy.
    Amstad A; Papagiannoulis E; Scherer A; Rubbert-Roth A; Finckh A; Mueller R; Dudler J; Möller B; Villiger PM; Schulz MMP; Kyburz D
    Rheumatology (Oxford); 2022 Dec; 62(1):89-97. PubMed ID: 35579338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional, biological disease-modifying anti-rheumatic drugs and Janus kinase inhibitors and varicella zoster virus.
    Atzeni F; Gozza F; Riva A; Alciati A; Galloway J
    Expert Opin Pharmacother; 2023 Apr; 24(6):679-689. PubMed ID: 36946287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of JAK inhibitor use in patients with rheumatoid arthritis who developed herpes zoster after receiving JAK inhibitors.
    Choi W; Ahn SM; Kim YG; Lee CK; Yoo B; Hong S
    Clin Rheumatol; 2022 Jun; 41(6):1659-1663. PubMed ID: 35157164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.